MCID: OST115
MIFTS: 42

Osteonecrosis of the Jaw

Categories: Bone diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Osteonecrosis of the Jaw

MalaCards integrated aliases for Osteonecrosis of the Jaw:

Name: Osteonecrosis of the Jaw 58 75

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare bone diseases


External Ids:

ICD10 via Orphanet 32 K10.2
UMLS via Orphanet 72 C2711248
Orphanet 58 ORPHA399293

Summaries for Osteonecrosis of the Jaw

Orphanet: 58 A rare osteonecrosis characterized by an exposed necrotic lesion in the mandible or maxilla present for more than eight weeks, arising as a complication of antiresorptive medication, dental interventions, or trauma and infections. Patients may present with pain, altered neurosensory functions, secondary infections, and (in advanced stages) pathological fractures, or fistulae.

MalaCards based summary: Osteonecrosis of the Jaw is related to osteonecrosis and periapical periodontitis. An important gene associated with Osteonecrosis of the Jaw is CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Chlorhexidine and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and bone marrow, and related phenotypes are growth/size/body region and renal/urinary system

Wikipedia: 75 Osteonecrosis of the jaw (ONJ) is a severe bone disease (osteonecrosis) that affects the jaws (the... more...

Related Diseases for Osteonecrosis of the Jaw

Diseases related to Osteonecrosis of the Jaw via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 309)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis 31.5 VEGFA TGFB1 NFATC1 IL17A CYP2C8
2 periapical periodontitis 30.5 SIRT1 IL17A
3 osteoporosis 30.2 VEGFA TGFB1 SIRT1 NFATC1 IL17A HLA-DRB1
4 pemphigus 30.0 IL17A HLA-DRB1 HLA-DQB1
5 bone inflammation disease 30.0 VEGFA IL17A HLA-DRB1
6 sarcoidosis 1 29.9 IL17A HLA-DRB1 HLA-DQB1
7 systemic scleroderma 29.8 VEGFA IL17A HLA-DRB1
8 autoimmune disease 29.7 TGFB1 IL17A HLA-DRB1 HLA-DQB1
9 hypothyroidism 29.6 VEGFA IL17A HLA-DRB1 HLA-DQB1
10 type 1 diabetes mellitus 29.6 VEGFA IL17A HLA-DRB1 HLA-DQB1
11 inflammatory bowel disease 28.9 TGFB1 NFATC1 IL17A HLA-DRB1 CYLD
12 dilated cardiomyopathy 28.8 VEGFA TGFB1 SIRT1 IL17A HLA-DRB1 HLA-DQB1
13 diabetes mellitus 28.5 VEGFA TGFB1 SIRT1 PARP1 IL17A HLA-DRB1
14 gnathodiaphyseal dysplasia 11.2
15 myeloma, multiple 11.0
16 bone disease 11.0
17 bone mineral density quantitative trait locus 8 10.9
18 bone mineral density quantitative trait locus 15 10.9
19 osteomyelitis 10.9
20 mammary paget's disease 10.8
21 rapidly involuting congenital hemangioma 10.7
22 periodontitis 10.7
23 twin-reversed arterial perfusion sequence 10.5
24 bone cancer 10.5
25 kidney cancer 10.5
26 renal cell carcinoma, nonpapillary 10.5
27 endosteal hyperostosis, autosomal dominant 10.5
28 prostate cancer 10.5
29 paget's disease of bone 10.5
30 actinomycosis 10.5
31 chronic recurrent multifocal osteomyelitis 10.5
32 rickets 10.5
33 rheumatoid arthritis 10.4
34 maxillary sinusitis 10.4
35 avascular necrosis 10.4
36 prostate cancer, hereditary, 8 10.4
37 brittle bone disorder 10.4
38 prostate cancer, hereditary, 6 10.4
39 fibrous dysplasia 10.4
40 breast cancer 10.4
41 tatton-brown-rahman syndrome 10.4
42 lymphoproliferative syndrome 10.4
43 mucositis 10.4
44 47 xxx syndrome 10.4
45 osteoporosis, juvenile 10.3
46 short stature, onychodysplasia, facial dysmorphism, and hypotrichosis 10.3
47 adult respiratory distress syndrome 10.3
48 gingivitis 10.3
49 collecting duct carcinoma 10.3
50 herpes zoster 10.3

Graphical network of the top 20 diseases related to Osteonecrosis of the Jaw:



Diseases related to Osteonecrosis of the Jaw

Symptoms & Phenotypes for Osteonecrosis of the Jaw

MGI Mouse Phenotypes related to Osteonecrosis of the Jaw:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.14 BCL6 CYLD HLA-DQB1 HLA-DRB1 IL17A NFATC1
2 renal/urinary system MP:0005367 10 HLA-DQB1 IL17A PARP1 SEMA4D SIRT1 TGFB1
3 immune system MP:0005387 10 BCL6 CYLD HERC4 HLA-DQB1 IL17A NFATC1
4 liver/biliary system MP:0005370 9.98 BCL6 HLA-DQB1 IL17A NFATC1 SIRT1 TGFB1
5 cellular MP:0005384 9.97 BCL6 CYLD HERC4 HLA-DQB1 NFATC1 PARP1
6 digestive/alimentary MP:0005381 9.91 CYLD HLA-DQB1 IL17A NFATC1 SIRT1 TGFB1
7 respiratory system MP:0005388 9.76 BCL6 CYLD HLA-DQB1 IL17A NFATC1 SIRT1
8 hematopoietic system MP:0005397 9.7 BCL6 CYLD HERC4 HLA-DQB1 IL17A NFATC1
9 integument MP:0010771 9.23 BCL6 CYLD IL17A NFATC1 PARP1 SIRT1

Drugs & Therapeutics for Osteonecrosis of the Jaw

Drugs for Osteonecrosis of the Jaw (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
2
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
3
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
4
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
5
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7 Antibiotics, Antitubercular Phase 4
8 Anti-Bacterial Agents Phase 4
9 Penicillins Phase 4
10 Anti-Infective Agents, Local Phase 4
11
Clindamycin phosphate Phase 4 32603
12 Clindamycin palmitate Phase 4
13 Chlorhexidine gluconate Phase 4
14 Disinfectants Phase 4
15 Amoxicillin-Potassium Clavulanate Combination Phase 4
16 Anti-Infective Agents Phase 4
17 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
18 Dermatologic Agents Phase 4
19
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
20
Tocopherol Approved, Investigational Phase 3 1406-66-2
21
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 3 59-02-9, 10191-41-0 2116 14985
22
Tocotrienol Investigational Phase 3 6829-55-6 9929901
23 Radiation-Protective Agents Phase 3
24 Vitamins Phase 3
25 Trace Elements Phase 3
26 Phosphodiesterase Inhibitors Phase 3
27 Vasodilator Agents Phase 3
28 Platelet Aggregation Inhibitors Phase 3
29 Antioxidants Phase 3
30 Micronutrients Phase 3
31 Protective Agents Phase 3
32 Tocotrienols Phase 3
33 Tocopherols Phase 3
34 Lidocaine, Prilocaine Drug Combination Phase 1, Phase 2
35 Angiogenesis Inhibitors Phase 1, Phase 2
36 Anesthetics Phase 1, Phase 2
37
Levofloxacin Approved, Investigational 100986-85-4 149096
38
Ofloxacin Approved 82419-36-1 4583
39
Parathyroid hormone Approved, Investigational 9002-64-6
40
Denosumab Approved 615258-40-7
41
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
42
Clotrimazole Approved, Vet_approved 23593-75-1 2812
43
Teriparatide Approved, Investigational 52232-67-4 16133850 155817470
44
Risedronic acid Approved, Investigational 105462-24-6 5245
45
Alendronic acid Approved 121268-17-5, 66376-36-1 2088
46
Etidronic acid Approved 2809-21-4, 7414-83-7 3305
47
Pamidronic acid Approved 40391-99-9 4674
48
Ibandronate Approved, Investigational 114084-78-5 60852
49
Tiludronic acid Approved, Investigational, Vet_approved 89987-06-4 60937
50
Cholecalciferol Approved, Nutraceutical, Vet_approved 67-97-0, 1406-16-2 5280795 10883523

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 A Multicenter Randomized Controlled Open-label Trial of Conservative Management Versus Minimally Invasive Treatment With Leukocyte- and Platelet-rich Fibrin Versus Primary Surgery in Patients With Newly Diagnosed Osteonecrosis of the Jaw Not yet recruiting NCT04512638 Phase 4 Antibiotics;Chlorhexidine mouthwash
2 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw: a Multicenter, Randomized, Clinical Trial Unknown status NCT03390777 Phase 2, Phase 3
3 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment Enrolling by invitation NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
4 OZOPROMAF: Validation Study of the Use of Ozonotherapy in Mronj Management- Protocol of Ozone by Infiltrations in Patients With Osteonecrosis of the Jaws Drug Related Suspended NCT05036837 Phase 1, Phase 2 OZOPROMAF_SEQ1
5 Prospective Randomized Clinical Study: Role of Platelet Rich Fibrin (PRF) in the Tooth Extraction Site in the Prevention of Jaw Osteonecrosis on Patients Under Bisphosphonates Therapy Unknown status NCT02198001 tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
6 Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay. Unknown status NCT02218554
7 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Unknown status NCT03418454
8 Efficacy and Safety on the Use of Bisphosphonates in Paediatrics Completed NCT04012320
9 Root Canal Treatment of Compromised Teeth as Alternative Treatment in Patients Under Bisphosphonate Therapy: 60-month Results of a Prospective Clinical Study Completed NCT04399720
10 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer Completed NCT01325142
11 A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway Completed NCT01967160
12 Trans-PBRN Case-control Study of Osteonecrosis of the Jaws Completed NCT01130389
13 Osteonecrosis of the Jaw (ONJ) Case Registry Completed NCT01666106
14 Retrospective Cohort Study of ONJ Completed NCT01201330
15 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study Completed NCT00858585
16 Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw Completed NCT01998607
17 S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment Completed NCT00874211
18 The Effect of Concentrated Growth Factor (CGF) in Surgical Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) in Osteoporosis Patients: a Randomized Controlled Study Completed NCT04531800
19 Conservative Versus Surgical Treatment for Medication Related Osteonecrosis of the Jaws (MRONJ) Stages I and II, a Quasi-experimental Clinical Trial With Discovery of Salivary Biomarkers Recruiting NCT04584840
20 International, Multicenter, Prospective Registry to Collect Data of Treatment Patterns of Patients With Medication-related Osteonecrosis of the Jaw (MRONJ) and Their Outcome Recruiting NCT02932501
21 Phototherapy With Low Level Laser in the Prevention and Treatment of Oral Lesions (Mucositis, Hyposalivation and Osteonecrosis) Resulting From Anti-neoplastic Treatment With Chemotherapy or Radiotherapy. Recruiting NCT04717765
22 Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects Active, not recruiting NCT01875458
23 Surgical Management of Stage-2 Medication-Related Osteonecrosis of the Jaw With Transplantation of Human Amniotic Membrane Active, not recruiting NCT04967963
24 Pilot Study: Local and Systemic Changes in Osteonecrosis of the Jawbone Enrolling by invitation NCT05329558
25 POPULATION PHARMACOMETRICS FOR ASSESSING RISK OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW (BRONJ) Withdrawn NCT02069340 zoledronic acid

Search NIH Clinical Center for Osteonecrosis of the Jaw

Genetic Tests for Osteonecrosis of the Jaw

Anatomical Context for Osteonecrosis of the Jaw

Organs/tissues related to Osteonecrosis of the Jaw:

MalaCards : Bone, Breast, Bone Marrow, Prostate, T Cells, Endothelial, Lung

Publications for Osteonecrosis of the Jaw

Articles related to Osteonecrosis of the Jaw:

(show top 50) (show all 2818)
# Title Authors PMID Year
1
Quantitative Real-Time Gene Profiling of Human Alveolar Osteoblasts Using a One-Step System. 62
36418701 2023
2
World Workshop on Oral Medicine VII: Oral adverse effects to biologic agents in patients with inflammatory disorders. A scoping review. 62
36455995 2022
3
A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives. 62
36458395 2022
4
Comparison of maximum and mean standardized uptake values of jaw pathologies with bone SPECT/CT: an especial focus on medication-related osteonecrosis of the jaw. 62
36345763 2022
5
Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points. 62
36318340 2022
6
Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points. 62
35882670 2022
7
Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam. 62
35941396 2022
8
Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database. 62
35933498 2022
9
Assessment of clinical guidelines for medication-related osteonecrosis of the jaw: current status and future directions. 62
36241597 2022
10
Platelet-derived growth factors from a single donor by apheresis and one freeze-thaw cycle for treating medication-related osteonecrosis of the jaw. 62
36169261 2022
11
Convolutional neural network for automated classification of osteonecrosis and related mandibular trabecular patterns. 62
36389628 2022
12
The Role of Bone Grafts in Preventing Medication-Related Osteonecrosis of the Jaw: Histomorphometric, Immunohistochemical, and Clinical Evaluation in Animal Model. 62
36387320 2022
13
Incidence and risk factors for medication-related osteonecrosis after tooth extraction in cancer patients-A systematic review. 62
36464958 2022
14
Correction to: Patients' quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw. 62
34841455 2022
15
Is medication related osteonecrosis of the jaw around implants a rare entity? A case series with a focus on etiopathophysiology. 62
34922047 2022
16
Re: AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update. 62
36332990 2022
17
A liquid chromatography-tandem mass spectrometry method for the quantification of ampicillin/sulbactam and clindamycin in jawbone, plasma, and platelet-rich fibrin: Application to patients with osteonecrosis of the jaw. 62
36435082 2022
18
Medication-related osteonecrosis of the jaw triggered by endodontic failure in oncologic patients. 62
36403223 2022
19
Organic Bone Matrix Component Type I and V Collagen Are Not Destructed in Bisphosphonate-Associated Osteonecrosis of the Jaws. 62
36422230 2022
20
Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study. 62
36166107 2022
21
The "Phoenix Jaw" Phenomenon Revisited: Two Cases of Bisphosphonate-Related Mandible Osteonecrosis Surgically Treated with Complete Bone Regeneration. 62
36123026 2022
22
Actinomycosis and osteonecrosis of the jaw: Every why hides a why. 62
35640875 2022
23
Medication-related osteonecrosis of the jaw: Prosthodontic considerations. 62
34984072 2022
24
Osteonecrosis of the jaw among cancer patients in Denmark: risk and prognosis. 62
35279336 2022
25
Long-term consequences of osteoporosis therapy with denosumab. 62
36382761 2022
26
Bone Concentration of Ampicillin/Sulbactam: A Pilot Study in Patients with Osteonecrosis of the Jaw. 62
36429636 2022
27
A comparative study of the clinical characteristics of patients with medication-related osteonecrosis of the jaw and osteoporosis or malignancy. 62
35668004 2022
28
Analysis of the effect of zoledronic acid on gene differences in rat jaw. 62
35390513 2022
29
Bone Morphogenetic Protein 2 Plus Leukocyte and Platelet-Rich Fibrin for the Treatment of MRONJ. 62
36217220 2022
30
Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro. 62
35171372 2022
31
Cytoprotective effect of Fridericia chica (Bonpl.) L.G. Lohmann extract associated with geranylgeraniol enriched-fraction from Bixa orellana L. on epithelial cells treated with bisphosphonate. 62
36226767 2022
32
Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: A retrospective cohort study. 62
36299343 2022
33
Maximum standardized uptake value of normal structures in the head and neck with bone SPECT/CT. 62
34989162 2022
34
Treatment outcomes of proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for locally advanced oral cancer in the elderly. 62
35125267 2022
35
Medication-related osteonecrosis of the jaw and successful implant treatment in a patient on high-dose antiresorptive medication: A case report. 62
35894761 2022
36
The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis. 62
36415385 2022
37
Reply to Potential Issues With the Use of Teriparatide After Denosumab-Related Osteonecrosis of the Jaw. 62
35924400 2022
38
Denosumab-Related Osteonecrosis of the Jaw May Not Be a Subject of Teriparatide Treatment. 62
35751544 2022
39
Beta tricalcium phosphate, either alone or in combination with antimicrobial photodynamic therapy or doxycycline, prevents medication-related osteonecrosis of the jaw. 62
36192619 2022
40
Idiopathic lingual mandibular sequestration and its relationship to medication-related osteonecrosis of the jaws (MRONJ): mini review. 62
36169274 2022
41
Association Between Malignant Diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis. 62
36184756 2022
42
Vascular Analysis of Soft Tissues Around the Bone Lesion in Osteoradionecrosis, Medication-Related Osteonecrosis, and Infectious Osteomyelitis of the Jaw. 62
36201691 2022
43
Medication-Related Osteonecrosis of the Jaw: 14 Years' Retrospective Study on Pathogenetic Trigger Events. 62
36201694 2022
44
Medication-related osteonecrosis of the jaw, a risk to reassess in osteoporotic patients. 62
36273739 2022
45
Medication-Related Osteonecrosis of the Jaw Associated in a Patient Treated With Etanercept. 62
35184115 2022
46
Possible association of methotrexate use with osteonecrosis of the jaw: Systematic review. 62
35306206 2022
47
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). 62
35312858 2022
48
Oral-Health-Related Quality of Life in Patients with Medication-Related Osteonecrosis of the Jaw: A Prospective Clinical Study. 62
36141982 2022
49
Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center. 62
36092518 2022
50
Osteonecrosis of the jaw in primary dental care: Recognition and referral. 62
36073051 2022

Variations for Osteonecrosis of the Jaw

Expression for Osteonecrosis of the Jaw

Search GEO for disease gene expression data for Osteonecrosis of the Jaw.

Pathways for Osteonecrosis of the Jaw

Pathways related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 VEGFA TGFB1 NFATC1 IL17A HLA-DRB1 HLA-DQB1
2
Show member pathways
12.96 BCL6 HLA-DQB1 HLA-DRB1 IL17A TGFB1 VEGFA
3 12.27 NFATC1 IL17A CYLD BCL6
4 12 TGFB1 HLA-DRB1 BCL6
5
Show member pathways
11.89 NFATC1 IL17A HLA-DRB1
6 11.45 TGFB1 SEMA4D NFATC1
7 11.29 VEGFA TGFB1 IL17A BCL6
8 11.27 TGFB1 NFATC1 IL17A
9 11.26 NFATC1 HLA-DRB1 HLA-DQB1
10 11.03 TGFB1 HLA-DRB1
11 10.99 VEGFA IL17A
12 10.99 VEGFA TGFB1 IL17A HLA-DRB1 HLA-DQB1
13 10.8 VEGFA TGFB1
14 10.77 TGFB1 SIRT1
15 10.76 VEGFA TGFB1 IL17A
16 10.73 SIRT1 PARP1
17 10.47 SIRT1 PARP1

GO Terms for Osteonecrosis of the Jaw

Biological processes related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.89 VEGFA TGFB1 SEMA4D
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.88 VEGFA SIRT1 SEMA4D
3 cellular response to transforming growth factor beta stimulus GO:0071560 9.83 TGFB1 PARP1 NFATC1
4 positive regulation of protein phosphorylation GO:0001934 9.81 VEGFA TGFB1 SIRT1 SEMA4D HLA-DRB1
5 positive regulation of transcription regulatory region DNA binding GO:2000679 9.69 TGFB1 PARP1
6 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 VEGFA TGFB1 SIRT1
7 positive regulation of vascular permeability GO:0043117 9.63 VEGFA TGFB1
8 positive regulation of smooth muscle cell differentiation GO:0051152 9.5 SIRT1 TGFB1
9 immunoglobulin production involved in immunoglobulin-mediated immune response GO:0002381 9.4 HLA-DRB1 HLA-DQB1
10 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.37 HLA-DRB1 HLA-DQB1
11 positive regulation of histone deacetylation GO:0031065 9.35 TGFB1 SIRT1 BCL6
12 macrophage differentiation GO:0030225 9.23 VEGFA SIRT1 PARP1 HLA-DRB1

Molecular functions related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.8 HLA-DRB1 HLA-DQB1

Sources for Osteonecrosis of the Jaw

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....